Analysts predict that CRH Medical Corporation (NASDAQ:CRHM) will announce $28.50 million in sales for the current quarter, Zacks reports. Two analysts have provided estimates for CRH Medical’s earnings. The highest sales estimate is $28.70 million and the lowest is $28.30 million. CRH Medical posted sales of $24.67 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 15.5%. The business is scheduled to announce its next quarterly earnings report on Monday, April 29th.
According to Zacks, analysts expect that CRH Medical will report full-year sales of $128.95 million for the current fiscal year, with estimates ranging from $125.45 million to $130.90 million. For the next fiscal year, analysts forecast that the firm will post sales of $143.17 million, with estimates ranging from $132.40 million to $158.00 million. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow CRH Medical.
CRH Medical (NASDAQ:CRHM) last announced its quarterly earnings data on Wednesday, March 13th. The company reported $0.02 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.02. The company had revenue of $32.02 million for the quarter, compared to analysts’ expectations of $31.40 million.
Shares of CRH Medical stock opened at $2.82 on Tuesday. CRH Medical has a one year low of $2.51 and a one year high of $4.50.
CRH Medical Company Profile
CRH Medical Corporation provides various products and services to gastroenterologists for the treatment of gastrointestinal diseases in the United States, Canada, and internationally. It offers CRH O'Regan system, a single use, disposable, and hemorrhoid banding technology for treating various grades of hemorrhoid.
See Also: Net Income
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CRH Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRH Medical and related companies with MarketBeat.com's FREE daily email newsletter.